This reduction in effect was especially pronounced for PTEN, a canonical negative regulator of the PI3K–AKT pathway, a central oncogenic signaling pathway in many cancer types which is activated through a variety of mechanisms in a large fraction of lung adenocarcinomas53–55. The gene discussed is AKT1; the disease is cancer.